FIELD: medicine, cardiology, pharmacy. SUBSTANCE: invention relates to the drug technology, in part, a method of making medicinal form of original domestic preparation diumancal-forte as tablets in the dose 0.01 g showing an anti-ischemic effect. Diumancal is a highly effective antagonist of calcium cations and used as an antianginal preparation for treatment of anti-ischemic heart disease in adults being in the drug form suitable for intake. EFFECT: improved method of tablets making, improved properties. 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICAMENT WITH PROLONGED ANTI-CALCIUM ACTIVITY IN THE FORM OF 1/10% INTRAVENOUS SOLUTION | 2004 |
|
RU2255728C1 |
| AGENT FOR TREATMENT OF PATIENT WITH HEART ISCHEMIC DISEASE | 1998 |
|
RU2155036C2 |
| DERIVATIVES OF 2-H-1-BENZOPYRANE-2-ONE ELICITING ANTI-CALCIUM ACTIVITY | 2003 |
|
RU2242471C1 |
| ANTICOAGULANT AGENT OF INDIRECT ACTION ON BASIS OF DIUMANCAL | 2018 |
|
RU2671983C9 |
| ANCARDIN-RETARD AS AGENT WITH PROLONGED ANTI-CALCIUM EFFECT | 2002 |
|
RU2219927C1 |
| ANTIARRHYTHMIC DRUG BASED ON HYBRID MOLECULES OF AMLODIPINE WITH (7-METHOXICUMARIN-4-YL)ACETIC ACID | 2018 |
|
RU2678969C1 |
| ANTIARRHYTHMIC MEDICATION BASED ON 4-METHYL-7,7'-ETHYLENEDIOXY-2H-1-DIBENZOPYRAN-2,2'-DIONE | 2010 |
|
RU2427368C1 |
| ANTICOAGULANT AGENT OF INDIRECTLY ACTION BASED ON NEW HYBRID MOLECULE OF WARFARIN WITH ESSENTIAL ACID | 2018 |
|
RU2677647C1 |
| HYBRID COUMARINS WITH INDIRECT ANTICOAGULANT ACTION | 2018 |
|
RU2672062C1 |
| ANTI-ISCHEMIC AND ANTI-ATHEROSCLEROTIC DRUG | 1998 |
|
RU2144822C1 |
